Sarah Arbe-Barnes
Overview
Explore the profile of Sarah Arbe-Barnes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inderberg E, Singh N, Miller R, Arbe-Barnes S, Eriksen H, Lversen B, et al.
Cancer Immunol Immunother
. 2025 Feb;
74(4):115.
PMID: 39998682
FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T cell responses targeting frameshift mutations of MSI-H cancers. FMPV-1 is designed to activate...
2.
Ramharter M, Djimde A, Borghini-Fuhrer I, Miller R, Shin J, Aspinall A, et al.
Malar J
. 2024 Feb;
23(1):61.
PMID: 38418982
Background: Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from three randomized clinical trials and a real-world study...
3.
Groger M, Lutete G, Assi S, Bigoga J, Ntamabyaliro N, Arbe-Barnes S, et al.
Int J Infect Dis
. 2023 Oct;
137:114-117.
PMID: 37871675
Global health, particularly in underserved settings can benefit immensely from well-trained community health workers (CHWs) supporting primary healthcare interventions. They can reduce morbidity and mortality of infectious diseases like malaria....
4.
Chandiwana N, Kruger C, Richardson N, Nxumalo S, Mashilo N, Dineka Y, et al.
Trials
. 2023 Oct;
24(1):635.
PMID: 37794489
Background: Repeated COVID-19 waves and corresponding mitigation measures have impacted health systems globally with exceptional challenges. In response to the pandemic, researchers, regulators, and funders rapidly pivoted to COVID-19 research...
5.
Chandiwana N, Kruger C, Johnstone H, Chughlay M, Ju C, Kim B, et al.
EBioMedicine
. 2022 Nov;
86:104322.
PMID: 36332361
Background: This exploratory study investigated four repurposed anti-infective drug regimens in outpatients with COVID-19. Methods: This phase 2, single centre, randomised, open-label, clinical trial was conducted in South Africa between...
6.
Groger M, Lutete G, Mombo-Ngoma G, Ntamabyaliro N, Kahunu Mesia G, Muena Mujobu T, et al.
Lancet Microbe
. 2022 Jun;
3(8):e598-e605.
PMID: 35654079
Background: High-quality evidence for the therapeutic efficacy and effectiveness of antimalarials for infections caused by Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections is scarce. In this study, we aimed...
7.
Lutete G, Mombo-Ngoma G, Assi S, Bigoga J, Koukouikila-Koussounda F, Ntamabyaliro N, et al.
PLoS Med
. 2021 Jun;
18(6):e1003669.
PMID: 34129601
Background: In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated malaria, pyronaridine-artesunate demonstrated high efficacy and a safety profile consistent with that of comparators, except that...
8.
Dabira E, Hachizovu S, Conteh B, Mendy A, Nyang H, Lawal B, et al.
Clin Infect Dis
. 2021 May;
74(2):180-188.
PMID: 33983371
Background: Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full...
9.
Morris C, Pokorny R, Lopez-Lazaro L, Miller R, Arbe-Barnes S, Duparc S, et al.
Antimicrob Agents Chemother
. 2014 Jul;
58(10):5900-8.
PMID: 25070091
The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day...
10.
Duparc S, Borghini-Fuhrer I, Craft C, Arbe-Barnes S, Miller R, Shin C, et al.
Malar J
. 2013 Feb;
12:70.
PMID: 23433102
Background: Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Methods: Individual patient data on safety outcomes were integrated from six randomized clinical...